Non-treated IGF-II transgenic mice did not develop ACF, whereas IGF-II transgenic mice treated with DMH exhibited significantly more ACF in an early phase of tumor development than the non-transgenic DMH-treated mice. The gene discussed is IGF2; the disease is neoplasm.